Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular DegenerationBusiness Wire • 06/29/21
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock OptionsZacks Investment Research • 05/20/21
Ocular Therapeutix's (OCUL) CEO Antony Mattessich on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business UpdateBusiness Wire • 05/05/21
CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingBusiness Wire • 05/03/21
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® SealantBusiness Wire • 05/03/21
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingBusiness Wire • 04/29/21
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/12/21
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business UpdateBusiness Wire • 03/11/21
Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic ConjunctivitisBusiness Wire • 03/04/21
Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye DiseaseBenzinga • 03/01/21
Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye DiseaseBusiness Wire • 03/01/21
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial ResultsBusiness Wire • 02/25/21
Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD StudyBenzinga • 02/16/21
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual EditionBusiness Wire • 02/12/21
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 02/04/21
Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons ForumBusiness Wire • 01/20/21